The SVF is the heterogeneous cell population left behind when adipose tissue is processed to remove mature fat cells. Unlike culture-expanded mesenchymal stem cells, which are grown in laboratories over weeks, the SVF can be isolated fresh and contains a mixture of stromal cells, pericytes, endothelial cells, and immune cells. Its secretome—the full complement of soluble factors, growth factors, cytokines, and extracellular vesicles that these cells release—differs in important ways from the conditioned media of cultured stem cells. Puspita’s review emphasizes that this distinction matters, because the freshly isolated secretome retains a biochemical complexity and pericyte-rich secretory activity that culture expansion can diminish or alter.

At the heart of the review lies a detailed mechanistic proposal centered on NF-κB, one of the most intensively studied signaling pathways in immunology. In resting cells, NF-κB transcription factors—in particular the p65/p50 dimer—sit inertly in the cytoplasm, tethered there by inhibitory proteins known as IκB. When pattern-recognition receptors on macrophages detect inflammatory triggers such as bacterial lipopolysaccharide, the IκB kinase, or IKK, complex phosphorylates IκBα, marking it for degradation. Freed from its anchor, NF-κB translocates into the nucleus and switches on a battery of genes encoding tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, inducible nitric oxide synthase, and cyclooxygenase-2. When this circuit fails to resolve, tissue damage accumulates and chronic inflammation takes hold.

According to the review, components of the SVF secretome are proposed to intervene at the earliest steps of this cascade. Specifically, they may modulate the phosphorylation of the IKK complex, thereby supporting the stabilization of IκBα. If IκBα remains intact, the p65/p50 dimer stays sequestered in the cytoplasm, and the nuclear translocation that drives inflammatory gene expression is hindered. The downstream consequence would be a measurable reduction in the output of pro-inflammatory mediators that perpetuate tissue destruction. Puspita suggests this mechanism could explain observations across multiple experimental systems in which adipose-derived secreted factors dampen inflammatory signaling in macrophages and other immune cells.

But blocking NF-κB is only half of the story. The review devotes equal attention to the second arm of the proposed mechanism: active reprogramming of macrophages away from the inflammatory M1 state and toward the reparative M2-like phenotype. Macrophages are remarkably plastic cells, and their polarization state is tightly coupled to their metabolism. Classically activated M1 macrophages rely predominantly on glycolysis, the rapid but inefficient glucose-burning pathway that supports their antimicrobial and inflammatory functions. Alternatively activated M2 macrophages, by contrast, depend on oxidative phosphorylation in their mitochondria, a metabolic mode that sustains their roles in tissue repair, debris clearance, and resolution of inflammation.

Puspita proposes that SVF secretome components encourage precisely this metabolic shift, pushing macrophages toward oxidative phosphorylation and thereby supporting M2-like polarization through the STAT6/PPAR-γ pathway. STAT6 is the signal transducer activated by interleukin-4 and interleukin-13, the canonical M2-polarizing cytokines, while PPAR-γ is a nuclear receptor whose activity reinforces the oxidative metabolic program and anti-inflammatory gene expression. By engaging this axis, the secretome would not merely silence inflammation but actively recruit macrophages into a regenerative identity—one that secretes interleukin-10, promotes angiogenesis, and rebuilds damaged extracellular matrix.

The interleukin-10 dimension deserves particular attention. This cytokine is among the most potent immunosuppressive molecules the body produces, acting through the STAT3 axis to restrain inflammatory responses in macrophages and regulatory T cells. Recent work highlighted in the review’s bibliography explores how extracellular vesicles can deliver stabilized, functional IL-10 to macrophages, and how the IL-10/STAT3/SOCS3 circuit contributes to anti-inflammatory effects in diverse disease models. Because SVF-derived extracellular vesicles can encapsulate cytokines, growth factors, and microRNAs, they may serve as natural delivery vehicles that concentrate and protect these immunomodulatory payloads, extending their half-life and targeting them to receptive cells within inflamed tissue.

The therapeutic implications span a remarkable range of chronic inflammatory conditions. In rheumatoid arthritis, the M1/M2 balance within the synovium is a well-documented determinant of disease severity, and shifting that balance toward M2 could reduce joint destruction. In inflammatory bowel disease, macrophage polarization via the STAT1 and STAT6 pathways has been shown to influence colitis outcomes in experimental models. Wound healing represents another promising arena: studies of mesenchymal secretome delivery in hydrogels have demonstrated suppression of neutrophil extracellular trap formation and acceleration of diabetic wound closure, while SVF combined with hyaluronic acid has shown benefits in bone regeneration models. Dermatology, adipogenesis, and neovascularization applications round out the translational landscape.

Yet the review is candid about the obstacles standing between laboratory promise and clinical reality. Chief among them is biochemical variability. The composition of the SVF secretome depends on the donor, the isolation method, the processing system used, and even the degree of tissue fragmentation, with microfragmented adipose tissue reported to contain higher pericyte content and greater secretory activity than enzymatically derived fractions. This heterogeneity complicates dosing, standardization, and regulatory approval. Puspita therefore recommends that future investigation establish standardized, GMP-compliant isolation methods and systematically evaluate how donor characteristics—age, sex, metabolic status, and health history—shape the secretome’s biochemical profile and therapeutic potency.

Safety considerations, at least, appear encouraging. An exhaustive literature review of autologous adipose-derived SVF in clinical use, cited in the review, suggests a favorable safety profile for the cell fraction itself, and the cell-free nature of secretome-based therapy sidesteps several risks associated with live cell transplantation, including unwanted engraftment and uncontrolled proliferation. Freeze-dried, GMP-compliant exosome formulations have already been proposed as stable pharmaceutical products for acellular immunomodulant therapy. If standardized SVF secretome preparations can be manufactured reproducibly and their mechanisms validated in rigorous preclinical and clinical studies, they could join a growing arsenal of cell-free regenerative medicines—offering patients with chronic inflammatory diseases a way to quiet the fire not by suppressing the immune system wholesale, but by teaching it, molecule by molecule, to heal.

Subject of Research: Immunomodulatory mechanisms of the adipose-derived Stromal Vascular Fraction secretome in NF-κB inhibition and macrophage reprogramming for chronic inflammatory disease treatment

Article Title: The role of the adipose-derived Stromal Vascular Fraction (SVF) secretome as an immunomodulator in the treatment of chronic inflammatory diseases through NF-κB and macrophage reprogramming

Article References: Puspita, R. (2026). The role of the adipose-derived Stromal Vascular Fraction (SVF) secretome as an immunomodulator in the treatment of chronic inflammatory diseases through NF-κB and macrophage reprogramming. Molecular Biology Reports, 53(1), Article 1604. https://doi.org/10.1007/s11033-026-12799-3

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12799-3

Keywords: Stromal Vascular Fraction, SVF secretome, NF-κB, macrophage polarization, M1/M2 macrophages, immunomodulation, adipose tissue, cell-free therapy, STAT6, PPAR-gamma, chronic inflammation, regenerative medicine

The central surprise of the study lies in the asymmetry of this crosstalk. When the team exposed human monocytes and macrophages to TNF and IL-4 together, they expected the classic pattern of mutual cross-inhibition that has dominated the literature on antagonistic cytokine pairs. What they observed instead was cooperation. TNF functioned predominantly as a partner that expanded and intensified the set of genes switched on by IL-4, rather than as a brake. The interleukin’s own signature was not blunted by the presence of the inflammatory signal; it was broadened by it. This finding suggests that the anti-inflammatory cytokine does not merely survive contact with its proinflammatory counterpart but actively exploits TNF signaling to shape the scope of its own transcriptional output.

The selectivity of the reverse direction is equally striking. IL-4 did not shut down TNF signaling wholesale. Instead, it targeted a specific component of the TNF-induced program: the interferon response. Genes driven by interferon regulatory pathways, which form an important antimicrobial and immune-activating arm of TNF signaling, were selectively inhibited by IL-4. The broader inflammatory gene expression elicited by TNF, however, remained largely intact. In other words, IL-4 pruned the interferon branch of the TNF response while leaving the rest of the inflammatory tree standing. This level of precision implies that the two cytokines negotiate at the level of individual gene programs rather than through a simple global on-off switch.

Among the genes that responded synergistically to the combined cytokines were sets with well-recognized roles in regulating inflammation and promoting tissue repair. When TNF and IL-4 were present together, these gene sets were induced to levels far exceeding what either cytokine achieved alone. The synergy was not a minor quantitative effect confined to a handful of transcripts; it encompassed coordinated gene programs that shape how macrophages behave in damaged tissue. Because macrophages are central orchestrators of the transition from inflammation to repair, the identity of the genes governed by this combined signal carries weight for understanding how wounds progress from the inflammatory phase to the rebuilding phase.

To test whether this laboratory-scale crosstalk mattered in a living tissue context, the investigators turned to a skin wound-healing model. Their analysis revealed that the synergistically induced gene sets were highly expressed during precisely the phase of wound repair when TNF and IL-4 are co-expressed in the healing tissue. This temporal overlap is biologically meaningful. It suggests that the cooperative program observed in cultured human monocytes is not an artifact of the dish but reflects a naturally occurring transcriptional state in which the two cytokines act together in time and space. During the window when inflammation and repair must be balanced, the combined TNF and IL-4 signal appears to help define the macrophage phenotype that supports that balance.

Mechanistically, the study traced the crosstalk to epigenetic chromatin-mediated mechanisms rather than to changes in signaling alone. Transcription factors are the proteins that bind DNA and switch genes on, but whether they can reach their targets depends on the state of the chromatin, the packaged form of DNA in the cell. The researchers found that cooperation between NF-κB, the canonical transcription factor activated by TNF, and STAT6, the transcription factor activated downstream of the IL-4 receptor, underpinned the synergistic gene expression. Rather than acting through separate gene sets, these two pathways converged on shared regulatory elements, allowing a proinflammatory signal and an anti-inflammatory signal to jointly open and activate the same loci.

A second epigenetic mechanism involved the erasure of a repressive histone mark. Histone H3 lysine 27 trimethylation, abbreviated H3K27me3, is a chemical modification of chromatin that is generally associated with silenced or po genes held in a inactive state. In the presence of the combined cytokine signal, this negative mark was removed from relevant genomic regions, lifting a layer of repression and permitting transcriptional activation. The removal of H3K27me3 provides a plausible explanation for how the synergy produces gene induction that neither cytokine can accomplish alone: TNF signaling through NF-κB helps remodel the chromatin landscape in a way that makes IL-4-driven, STAT6-dependent transcription possible at genes that would otherwise remain closed.

The third mechanistic pillar was the selective inhibition of IRF1, a transcription factor that mediates interferon responses and contributes to the interferon arm of TNF signaling. By suppressing IRF1, IL-4 was able to disassemble the interferon component of the TNF program without dismantling TNF-driven inflammatory gene expression more broadly. This selective targeting helps explain the otherwise paradoxical combination of results: cooperation at repair-related and inflammation-regulating genes on one hand, and selective antagonism at interferon-responsive genes on the other. The crosstalk is therefore not a single mechanism but a coordinated set of chromatin-level events that produce different outcomes at different classes of target genes.

The authors frame these results as identifying a mechanism for the expansion of the IL-4 response, and the implications extend beyond basic cytokine biology. If TNF signaling is required for the full breadth of the IL-4 program in monocytes and macrophages, then broadly suppressing TNF, as many anti-TNF therapies do in conditions such as rheumatoid arthritis and inflammatory bowel disease, may have consequences that reach into the tissue-repair arm of immunity, not only the inflammatory arm. The study also highlights the complexity of crosstalk between antagonistic cytokines more generally, showing that pairs of signals long assumed to cancel each other out can instead cooperate on select gene responses that are important for immune function and tissue repair. Cross-inhibition, the traditional focus of the field, turns out to be only part of the story.

As with any study, the findings come with scope conditions worth keeping in view. The human cell work was performed in primary monocytes and macrophages, and the in vivo evidence comes from a skin wound-healing model, so extending the conclusions to other tissues, other disease settings, and other cytokine combinations will require further investigation. Nevertheless, the work offers a concrete and testable framework: antagonistic cytokines negotiate through transcription factor cooperation, targeted histone modification, and selective inhibition of intermediary factors such as IRF1. For a field that has long organized itself around the idea that inflammatory and anti-inflammatory signals are opponents, the demonstration that TNF can serve as a costimulator of the IL-4 program, and that the two jointly govern genes central to repair, is a reminder that the immune system’s wiring is built less on simple opposition than on context-dependent partnership.

Subject of Research: Crosstalk between the cytokines TNF and IL-4 in regulating gene expression in human monocytes and macrophages

Article Title: IL-4 exploits TNF signaling to shape its gene expression signature in monocytes and macrophages

Article References: Yuan, R., Yang, C., Mishra, B., Oliver, D., Bell, R. D., & Ivashkiv, L. B. (2026). IL-4 exploits TNF signaling to shape its gene expression signature in monocytes and macrophages. Nature Communications. https://doi.org/10.1038/s41467-026-78528-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78528-3

Keywords: IL-4, TNF, monocytes, macrophages, cytokine crosstalk, NF-kB, STAT6, H3K27me3, IRF1, gene expression, wound healing, immunology

Solitary fibrous tumours are spindle cell neoplasms of mesenchymal origin, meaning they arise from connective tissue cells rather than from the epithelial cells that give rise to the vast majority of lung cancers. Most solitary fibrous tumours of the chest originate from the pleura, the thin membrane enveloping the lungs, and they are typically slow-growing and benign. When they occur inside the lung parenchyma instead, they become a genuine clinical curiosity. Published analyses suggest these intrapulmonary tumours most often affect adults between 50 and 70 years of age, and a clinicopathological review of 52 cases found a mean age of onset of 52.7 years, with the left lower lobe being the most frequently affected pulmonary location. That detail matters here, because the tumour in this new case arose in precisely that region.

The patient’s story began seven months before her definitive diagnosis, when a left-sided pleural effusion, an accumulation of fluid around the lung, was discovered incidentally during a hospital admission for hypoglycaemia. She had a history of diabetes mellitus, passive exposure to tobacco smoke, and more than two decades of employment in a textile factory. Initial chest radiography showed a homogeneous opacity in the left lower lung field accompanied by the effusion. Because tuberculosis remains a leading cause of pleural disease in many parts of the world, her physicians administered an empirical two-month course of anti-tuberculosis treatment. It failed. The opacity did not budge, a signal that something other than infection was occupying her chest.

Contrast-enhanced computed tomography performed in July 2025 finally revealed the true scale of the problem: a large mass in the left lower lobe measuring 14.1 by 15.6 by 12.1 centimetres. The patient was then lost to follow-up for more than five months, and when she returned with worsening chest pain and shortness of breath, repeat imaging showed that the tumour had grown to 11 by 16.5 by 15.2 centimetres. The mass was displacing her heart toward the right side of her chest, causing collapse of portions of the surrounding lung, and was accompanied by both pericardial and pleural effusions. Most ominously, a 3.8-centimetre nodule had appeared in the liver, suspicious for metastasis. Under the standard tumour-node-metastasis framework, the findings were classified as T4N0M1b, indicating a locally advanced tumour with possible distant spread but no involved lymph nodes.

A core needle biopsy of the mass yielded the tissue that would settle the diagnosis. Under the microscope, pathologists saw a low-grade spindle cell neoplasm with only one to two mitoses per ten high-power fields, a measure of how actively the cells were dividing. The decisive evidence came from immunohistochemistry, the technique that uses antibodies to detect specific proteins in tissue sections. The tumour cells showed diffuse nuclear positivity for STAT6, partial positivity for CD34, and a Ki-67 proliferation index below 5 percent, while staining for CK7, desmin, smooth muscle actin and S100 was negative. Diffuse nuclear STAT6 expression is regarded as a highly sensitive and specific marker for solitary fibrous tumours, reflecting the characteristic NAB2-STAT6 gene fusion that drives these neoplasms, and it is particularly valuable for distinguishing them from the many other spindle cell tumours that can arise in the chest.

The size of this tumour alone sets it apart. Radiologically, pulmonary solitary fibrous tumours typically present as well-circumscribed soft-tissue masses, and the majority of reported tumours measure less than 10 centimetres. A comparable giant presentation was described in a 2025 case report, in which a mass measuring 14 by 12 by 23 centimetres caused compressive atelectasis and raised concern for hepatic and splenic metastases. The combination in the current patient of massive tumour burden, compressive effects on the heart and mediastinum, suspected pericardial involvement and possible distant spread represents an unusually aggressive-looking profile for a tumour whose microscopic features still looked comparatively indolent.

One intriguing thread in the case is the patient’s earlier episode of hypoglycaemia. Solitary fibrous tumours are among the rare neoplasms capable of secreting insulin-like growth factor 2, a hormone-like protein that can drive blood sugar to dangerously low levels. This paraneoplastic phenomenon is known as Doege-Potter syndrome, and fewer than 2,000 cases have been reported worldwide. The connection is more than a medical curiosity: in a patient with a known fibrous tumour, unexplained hypoglycaemia can be a clue to the tumour’s biology, and resection of the tumour typically abolishes the metabolic derangement. In this case, however, serum IGF-2 levels were never measured, so the physicians could not formally confirm that the earlier hypoglycaemic episode was tumour-driven, leaving the association suggestive but unproven.

Pathologists weigh several features when judging whether a solitary fibrous tumour is likely to behave badly. Size greater than 10 centimetres, necrosis, increased mitotic activity, hypercellularity and nuclear pleomorphism all raise concern for malignant behaviour. The present tumour sailed past the size threshold and had radiographic evidence of possible metastasis, yet its mitotic count and Ki-67 index pointed toward low-grade histology. This tension between benign-looking cells and clinically ominous behaviour is precisely what makes solitary fibrous tumours so difficult to manage, and it underscores why diagnosis cannot rest on any single test. The authors emphasise that integrating clinical findings, imaging, histopathology and immunohistochemistry is essential to reaching an accurate diagnosis and tailoring treatment to the individual patient.

For localized solitary fibrous tumours, complete surgical resection remains the treatment of choice, and long-term survival after clean excision is generally excellent. But in this patient, a multidisciplinary team concluded that the extent of disease and the suspicion of metastatic spread made upfront surgery too risky. Systemic therapy became the pragmatic alternative, even though the evidence base for chemotherapy in advanced solitary fibrous tumours remains thin. Anthracycline-based regimens are commonly employed in unresectable or metastatic cases, and targeted approaches, including combinations of temozolomide with bevacizumab and the kinase inhibitors pazopanib and sunitinib, have shown promising results in refractory disease. The patient received six cycles of a four-drug regimen combining doxorubicin, cisplatin, vincristine and cyclophosphamide.

Follow-up imaging after chemotherapy showed a persistent mass measuring 16.2 by 9.0 by 14.7 centimetres with suspected invasion of the pericardium, the sac surrounding the heart, but no mediastinal lymphadenopathy. Pulmonary function testing revealed mild impairment of the lung’s diffusing capacity, with a DLCO of 67 percent of predicted, while standard spirometry was preserved. Clinically, the patient remained stable. The case, reported by Desdiani Desdiani and colleagues, is a reminder that even in an era of sophisticated imaging and molecular diagnostics, the rarest tumours still test the limits of clinical intuition. A mass that mimics tuberculosis, grows to the size of a small melon, shifts the heart within the chest and seeds a suspicious lesion in the liver demands that physicians hold every diagnostic tool in view at once, and that pathologists, radiologists and oncologists work in close concert to chart a course through genuinely uncharted territory.

Subject of Research: A rare giant intrapulmonary solitary fibrous tumour with suspected liver metastasis

Article Title: Giant Intrapulmonary Solitary Fibrous Tumour With a Possible Liver Metastasis: A Rare Case

Article References: Desdiani, D., Siregar, N. C., Prawiro, A., & Syahbunan, K. K. C. (2026). Giant Intrapulmonary Solitary Fibrous Tumour With a Possible Liver Metastasis: A Rare Case. Respirology Case Reports, 14(10), Article e70754. https://doi.org/10.1002/rcr2.70754

Image Credits: AI Generated

DOI: 10.1002/rcr2.70754

Keywords: solitary fibrous tumour, intrapulmonary tumour, STAT6, lung cancer, Doege-Potter syndrome, metastasis, immunohistochemistry, chemotherapy, case report, rare disease, spindle cell neoplasm, pleural effusion